Insulin degludec biosimilar（Jilin Huisheng）

德谷胰岛素生物类似药(吉林惠升)

Report date: 2026/03/09 20:02:04

Base Information

Drug NameInsulin degludec biosimilar（Jilin Huisheng）
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryMainland China
Original Approved Date2024/08/05
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJilin Huisheng Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJilin Huisheng Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A